Could a Weight-Loss drug change how your body handles alcohol?

NCT ID NCT07758231

Not yet recruiting Knowledge-focused Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study investigates whether tirzepatide, a medication used for weight loss, alters the way the body processes alcohol. Five adults aged 21-55 who take tirzepatide will consume a standard amount of alcohol, and researchers will measure blood alcohol levels, elimination rates, and subjective effects. The goal is to understand potential interactions between this popular drug and alcohol.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (Zepbound) and an acute dose of alcohol (vodka)
What this could lead to: If tirzepatide changes how the body handles alcohol, it could inform safer drinking guidelines for people taking this weight-loss medication.
What could go wrong: This is a very small early-phase study with only 5 participants, so results may not apply broadly. Alcohol can cause intoxication and impair judgment, and the study measures short-term effects only.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL GLP-1

Contacts and locations

Locations

University of Wisconsin

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.